Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $313000.0 in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 56.35% year-over-year to $313000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $313000.0 (down 56.35% YoY) and the FY2025 annual result came in at $317000.0, down 55.35% from the prior year.
• Non-Current Deferred Tax Liability slipped to $313000.0 in Q1 2026 per HBIO's latest filing, from $317000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.4 million in Q2 2022 and bottomed at $313000.0 in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $717000.0 (2025), against an average of $826882.4.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability surged 54.39%; it then sank 72.52% in 2023.
• Tracing HBIO's Non-Current Deferred Tax Liability over 5 years: stood at $590000.0 in 2022, then surged by 31.53% to $776000.0 in 2023, then declined by 8.51% to $710000.0 in 2024, then slumped by 55.35% to $317000.0 in 2025, then declined by 1.26% to $313000.0 in 2026.
• Per Business Quant, the three latest HBIO Non-Current Deferred Tax Liability figures stand at $313000.0 (Q1 2026), $317000.0 (Q4 2025), and $733000.0 (Q3 2025).

Peer Comparison